Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Alkermes plc Stock

Price
Target price
€24.80

€24.80

2.480%
0.6
2.480%
€38.70

€38.70

 
Buy 17 Sell 0
Buy 17
Sell 0
12.12.25 / Stuttgart Stock Exchange WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Stock / Biotechnology & Medical Research / Mid Cap /
Latest predictions
€47.38
17.11.25
-6.87%
buy
€31.93
13.11.25
-8.27%
buy
€38.83
13.11.25
-9.63%
buy
€43.28
11.11.25
-14.69%
buy
€36.06
29.10.25
-6.77%
buy
€48.04
28.10.25
-7.58%
buy
Show more
Your prediction
Pros and Cons of Alkermes plc in the next few years
Wizard

Alkermes plc Stock

There is an upward development for Alkermes plc compared to yesterday, with an increase of €0.60 (2.480%).
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Alkermes plc.
With a target price of 38 € there is a hugely positive potential of 53.23% for Alkermes plc compared to the current price of 24.8 €.
What does Alkermes do?

Pros and Cons of Alkermes plc in the next few years

Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Alkermes plc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Alkermes plc 2.480% -0.800% -7.463% -14.483% -11.429% 5.218% 40.909%
Icon plc -0.280% -0.345% 12.642% -20.989% -22.603% -14.027% -
Novocure Ltd -1.160% 9.135% 15.722% -60.508% -61.023% -84.133% -91.990%
Ironwood Pharmaceuticals -2.550% 4.795% 19.531% -8.383% -27.143% -73.167% -68.934%

Comments

Prediction Buy
Perf. (%) -6.87%
Target price 47.383
Change
Ends at 17.11.26

Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a "buy" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Show more

Truist Financial Co. 
0
Report Share
17.11.25
Prediction Buy
Perf. (%) -8.27%
Target price 31.927
Change
Ends at 13.11.26

Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $37.00. They now have an "overweight" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Show more

Wells Fargo & Company 
0
Report Share
13.11.25
Prediction Buy
Perf. (%) -9.63%
Target price 38.831
Change
Ends at 13.11.26

Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $55.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for ALKS provided by MarketBeat
Show more

Deutsche Bank Aktiengesellschaft 
0
Report Share
13.11.25
Show more
Not a member yet? Sign up for free!

News

Alkermes Q2 Sales Up 14 Percent
Alkermes Q2 Sales Up 14 Percent

Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus

TheMotleyFool 
0 29.07.25